GlassScriptPhysician profile
Caroline M Scherer
NPI 1659780922
$3,215.41
in general payments reported to CMS, 2019-2025
33 companies · $800 in 2025
The $800 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $502 · 2023: $748 · 2024: $956 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,504.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $620.99 | 2021-2025 | |
| Novo Nordisk INC | $508.70 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $348.72 | 2021-2024 | Tacticath Ablation Catheter, Sensor Enabled, Jot Dx, Aveir |
| Exact Sciences Corporation | $202.62 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $139.87 | 2021-2025 | Otezla, Repatha, Evenity |
| Corium, LLC | $129.06 | 2023-2025 | Azstarys |
| Pfizer INC. | $120.34 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $105.45 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $98.69 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Boston Scientific Corporation | $85.71 | 2025 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Glaxosmithkline, LLC. | $85.07 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.85 | 2022-2025 | Jardiance, Synjardy |
| Alkermes, INC. | $67.20 | 2025 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $56.26 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $55.22 | 2023-2025 | Ingrezza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $51.59 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $46.61 | 2022-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.28 | 2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $44.23 | 2022-2024 | |
| Shield Therapeutics INC | $36.61 | 2024 | |
| Amarin Pharma, INC. | $33.78 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.29 | 2022-2023 | |
| Avadel Cns Pharmaceuticals, LLC | $31.12 | 2025 | Lumryz |
| Currax Pharmaceuticals LLC | $27.71 | 2021-2023 | Contrave, Onzetra Xsail |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.60 | 2022-2023 | |
| Pharming Healthcare, INC. | $23.86 | 2024 | Ruconest |
| Azurity Pharmaceuticals, INC. | $19.36 | 2024 | Edarbi |
| Heartflow, INC. | $17.82 | 2025 | |
| Supernus Pharmaceuticals, INC. | $15.26 | 2021 | |
| Merck Sharp & Dohme LLC | $15.25 | 2022 | |
| Eisai INC. | $14.51 | 2021 | |
| Neos Therapeutics, LP | $13.51 | 2022 | |
| Hikma Pharmaceuticals USA | $13.27 | 2023 | Ryaltris, Mitigare |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Scherer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.